In other words, although VEGF is a commonly used target of new biological therapies that aim to block the angiogenic pathway, there was limited evidence that the SNPs in the VEGF gene lack sufficient predictive ability as biomarkers, only from the perspective of chemotherapeutic responsiveness, to identify whether patients with CRC should add anti-angiogenic agents to their chemotherapy regimens. This evidence concerns the gene VEGFA and colorectal carcinoma.